WO2008150937A2 - Pcr (amplification en chaîne par polymérase) en temps réel - Google Patents

Pcr (amplification en chaîne par polymérase) en temps réel Download PDF

Info

Publication number
WO2008150937A2
WO2008150937A2 PCT/US2008/065181 US2008065181W WO2008150937A2 WO 2008150937 A2 WO2008150937 A2 WO 2008150937A2 US 2008065181 W US2008065181 W US 2008065181W WO 2008150937 A2 WO2008150937 A2 WO 2008150937A2
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
rna
oligonucleotide
cdna
molecule
Prior art date
Application number
PCT/US2008/065181
Other languages
English (en)
Other versions
WO2008150937A3 (fr
Inventor
Mark G. Erlander
Original Assignee
Aivaradx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aivaradx, Inc. filed Critical Aivaradx, Inc.
Publication of WO2008150937A2 publication Critical patent/WO2008150937A2/fr
Publication of WO2008150937A3 publication Critical patent/WO2008150937A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]

Definitions

  • the disclosure relates to real-time PCR to detect the expression level(s) of genetic material in a sample.
  • the expression level of any gene sequence in the form of messenger RNA (mRNA) molecules, may be detected and/or quantified.
  • the disclosed methods may be used for RNA profiling, or determining the expression levels of multiple gene sequences in a biological sample, including a sample containing relatively degraded RNA.
  • the disclosure includes methods to use real-time polymerase chain reaction (PCR) to qualitatively detect, or quantitatively determine, the expression of one or more gene sequences in an RNA containing biological sample.
  • the methods include 1) combined cDNA synthesis, annealing of oligonucleotides followed by their extension, and ligation of the extension product; 2) use of PCR with primer sequences present in the oligonucleotides; and 3) real-time PCR mediated assaying of an RNA sequence present within the cDNA molecule.
  • the disclosed methods may be used to assay for the expression of RNA sequences in a variety of cell containing biological samples, such as archival, freshly frozen, and fresh samples.
  • the methods are suitable for use as a robust clinical assay to detect expression level(s) for comparison to archival or other referential samples.
  • the robustness of the methods includes the feature of consistency between samples and assay runs, which are provided in part by the real-time PCR portions of the method. With the use of real-time PCR to detect the product PCR amplicon, the methods do not rely upon a hybridization reaction to the amplicon as the means to determine the relative amount of a RNA sequence of interest.
  • a hybridization reaction directed to a target or unique sequence in the amplified material is necessarily limited by the technical challenges of limited linearity (of about 2 to about 3 logs) and variability between assay runs. Both of these limitations are reduced and/or eliminated by the disclosed methods, where real-time PCR has been highly regarded as a standard for quantifying mRNA expression because of its linearity (about 8 to 9 logs), sensitivity to a single copy, and reproducibility between independent runs or experiments.
  • the disclosure includes the identification and use of gene expression patterns (or profiles or “signatures”) by use of the disclosed method.
  • the gene expression profiles may be viewed as being embodied in a nucleic acid expression, or mRNA, format which may be elucidated, interrogated, or studied by use of the disclosed method.
  • the disclosure includes a method to identify, and then detect, gene expression profiles by use of real-time PCR.
  • the method may be used to detect the presence, and optionally the amount of, an RNA sequence present as a part of an RNA molecule or a counterpart cDNA molecule.
  • the method includes synthesizing a first, single-stranded cDNA molecule as a counterpart to an RNA molecule containing an RNA sequence to be detected.
  • the synthesis can be readily accomplished by reverse transcription of the RNA molecule by methodologies known to the skilled person, such as the use of a primer that hybridizes to the polyadenylated (polyA) tail of an RNA molecule or the use of a primer that hybridizes to a particular sequence within the RNA molecule via basepair complementarity.
  • the primer may contain an oligo dT sequence to permit hybridization to the polyA sequence.
  • RNA molecule may be one of a plurality of RNA molecules present in a sample.
  • Non-limiting examples include nucleic acid containing samples from a plant, animal, bacterium, or virus.
  • the sample is obtained from one or more cells from an animal or a human patient.
  • the method further includes annealing first and second DNA oligonucleotides to the single-stranded cDNA molecule.
  • the cDNA molecule which is complementary to all or part of the original RNA molecule template and is complementary to the RNA sequence to be detected, serves as a template upon which the first oligonucleotide may be extended.
  • the first oligonucleotide contains a sequence complementary to the cDNA molecule and contains a forward primer (FP) sequence at its 5' end.
  • the sequence complementary to the cDNA molecule may be complementary to all or part of the cDNA molecule's sequence that is complementary to an RNA sequence to be detected present in the original RNA molecule.
  • sequence complementary to the cDNA molecule would thus include all or part of an RNA sequence to be detected in the form of a DNA counterpart to the RNA sequence. So if the RNA sequence to be detected included the sequence AUG, the sequence complementary to the cDNA molecule would include the sequence ATG.
  • the sequence complementary to the cDNA molecule may not contain any portion of the RNA sequence to be detected in the form of a DNA counterpart to the RNA sequence. But in such a case, the sequence complementary to the cDNA molecule may be extended from the 3' end of the first oligonucleotide (such as by a DNA polymerase activity under suitable conditions) to include a portion containing all or part of an RNA sequence to be detected in the form of a DNA counterpart to the RNA sequence.
  • the FP sequence is not necessarily complementary to the cDNA molecule and may contain a unique sequence to facilitate subsequent hybridization to a PCR primer sequence and amplification by PCR.
  • the second oligonucleotide contains, at its 5' end, a sequence complementary to the cDNA molecule.
  • the second oligonucleotide also contains, at its 3' end, a sequence that is not complementary to the cDNA molecule such that extension, via use of the cDNA molecule as a template, is not generally possible. This sequence at the 3' end may be used as a reverse primer (RP) sequence as described herein.
  • RP reverse primer
  • the first and second oligonucleotides anneal to non-overlapping portions of the cDNA molecule, and in an orientation such that extension from the 3' end of the first oligonucleotide (such as by a DNA polymerase activity under suitable conditions) lengthens the first oligonucleotide toward the 5' end of the second oligonucleotide.
  • the first and second oligonucleotides are non-overlapping but spaced so that the 3' end of the first oligonucleotide may be ligated to the 5' end of the second oligonucleotide without the need for strand extension of the first oligonucleotide.
  • the method includes said extension before ligation with the second oligonucleotide.
  • the ligating of the two oligonucleotides may be performed by use of a ligase activity under suitable conditions. Ligation of the two oligonucleotides forms a second DNA strand with a portion complementary to the cDNA molecule. That portion will include a DNA counterpart sequence to all or part of an RNA sequence to be detected. The second DNA strand will serve as a DNA template for subsequent manipulation and analysis.
  • the second DNA strand will include the FP sequence from the 5' end of the first oligonucleotide and the RP sequence from the 3' end of the second oligonucleotide. These primer sequences are then used to amplify the second DNA strand.
  • the amplification may be by PCR to produce multiple copies of an amplicon, followed by real-time PCR as described below, or may be by real-time PCR alone.
  • the PCR conditions may include the use of forward and reverse primers that are exactly complementary to the FP and RP sequences present in the second DNA strand, respectively.
  • the forward and/or reverse primers may be complementary to portions of the FP and/or RP sequences sufficient to permit PCR.
  • the amplicon will include a DNA counterpart sequence to all or part of an RNA sequence to be detected.
  • the amplicon will include a detectable reporter (or "address") sequence present from the second oligonucleotide.
  • the RNA sequence to be detected can then be detected by use of real-time PCR that detects either, or both, strands of the amplicon.
  • the detection by realtime PCR may be mediated by detecting a reporter (or "address") sequence present in the amplicon.
  • the real-time PCR may include the use of a probe that hybridizes to a sequence within the region amplified by the primers used.
  • the probe is complementary to (or overlaps with) a portion of one of the two primers used.
  • a probe may be labeled with a donor fluorescent moiety and a second quencher or acceptor fluorescent moiety.
  • the probe may be a Taqman probe.
  • the real-time PCR conditions may include the use of forward and reverse primers as described herein for standard PCR. Additionally, the real-time PCR will include the use of probe as described herein.
  • the method may include the labeling of the cDNA molecule complementary to all or part of the RNA molecule to be detected.
  • Non-limiting examples include biotinylation of the cDNA molecule, such as by use of a biotinylated primer during reverse transcription.
  • the cDNA molecule is isolated or immobilized prior to use.
  • Non-limiting examples include isolation, or immobilization on a solid support, via a biotin label present on the cDNA molecule.
  • Methods to isolate or immobilize labeled cDNA molecules are known to the skilled persona and include the use of strepavidin linked beads or columns where the label is biotin. The isolation or immobilization may advantageously occur prior to the annealing of any oligonucleotide to the cDNA molecule.
  • Figure 1 is a schematic illustration of one embodiment of the disclosure.
  • a gene expression "pattern” or “profile” or “signature” refers to the relative expression of a gene between two or more cells or cell types, such as that between normal and diseased or cancerous cells.
  • a "gene” is a polynucleotide that encodes a discrete product, whether RNA or proteinaceous in nature. It is appreciated that more than one polynucleotide may be capable of encoding a discrete product.
  • the term includes alleles and polymorphisms of a gene that encodes the same product, or a functionally associated (including gain, loss, or modulation of function) analog thereof, based upon chromosomal location and ability to recombine during normal mitosis.
  • a "polynucleotide” or “oligonucleotide” is a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Thus, this term includes double- and single-stranded DNA and RNA. It also includes known types of modifications including labels known in the art, methylation, "caps", substitution of one or more of the naturally occurring nucleotides with an analog, and internucleotide modifications such as uncharged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), as well as unmodified forms of the polynucleotide.
  • uncharged linkages e.g., phosphorothioates, phosphorodithioates, etc.
  • a “probe” is a suitably labeled polynucleotide or oligonucleotide for use in real-time PCR.
  • a non-limiting example is a Taqman probe.
  • amplify is used in the broad sense to mean creating an amplification product can be made enzymatically with DNA or RNA polymerases.
  • Amplification generally refers to the process of producing multiple copies of a desired sequence, particularly those of a sample.
  • Multiple copies mean at least 2 copies.
  • a “copy” does not necessarily mean perfect sequence complementarity or identity to the template sequence.
  • a polynucleotide containing a sequence that is unique is used as a primer or probe disclosed herein.
  • Exemplary polynucleotides of this type contain at least about 20, at least about 22, at least about 24, at least about 26, at least about 28, at least about 30, or at least about 32 consecutive basepairs of a sequence that is not found in other polynucleotides present with the sequence complementary to the primer or probe.
  • the term "about” as used in the previous sentence refers to an increase or decrease of 1 from the stated numerical value.
  • Additional embodiments include polynucleotides of at least or about 50, at least or about 100, at least about or 150, at least or about 200, at least or about 250, at least or about 300, at least or about 350, or at least or about 400 basepairs of a gene sequence that is not found in other polynucleotides present with the sequence complementary to the primer or probe.
  • the term "about” as used in the preceding sentence refers to an increase or decrease of 10% from the stated numerical value.
  • polynucleotides may also be referred to as polynucleotide probes that are capable of hybridizing to sequences of a gene, or unique portion(s) thereof, to be detected as described herein.
  • the sequences may be those of an mRNA molecule encoded by a gene, the corresponding cDNA to such an mRNA molecule, and/or amplified versions of such sequences.
  • the polynucleotide may be an oligonucleotide or primer as described herein.
  • support refers to conventional supports such as beads, particles, dipsticks, fibers, filters, membranes and silane or silicate supports such as glass slides.
  • a "biological sample” or “cell containing sample” refers to a sample of cells or tissue isolated from an individual.
  • the sample may be from material removed via a surgical or non-surgical procedure, including, but not limited to, surgical biopsy.
  • Such samples are primary isolates (in contrast to cultured cells) and may be collected by any suitable means recognized in the art.
  • “Expression” and “gene expression” include transcription and/or translation of nucleic acid material.
  • Conditions that "allow” an event to occur or conditions that are “suitable” for an event to occur are conditions that do not prevent such events from occurring. Thus, these conditions permit, enhance, facilitate, and/or are conducive to the event.
  • Such conditions known in the art and described herein, depend upon, for example, the nature of the nucleotide sequence, temperature, and buffer conditions. These conditions also depend on what event is desired, such as hybridization, cleavage, strand extension or transcription.
  • Sequence "mutation,” as used herein, refers to any sequence alteration in the sequence of a gene disclosed herein interest in comparison to a reference sequence.
  • a sequence mutation includes single nucleotide changes, or alterations of more than one nucleotide in a sequence, due to mechanisms such as substitution, deletion or insertion.
  • Single nucleotide polymorphism (SNP) is also a sequence mutation as used herein. Because the present invention is based on the relative level of gene expression, mutations in non-coding regions of genes as disclosed herein may also be assayed in the practice of the invention.
  • Detection includes any means of detecting, including direct and indirect detection of gene expression and changes therein. For example, “detectably less” products may be observed directly or indirectly, and the term indicates any reduction (including the absence of detectable signal). Similarly, “detectably more” product means any increase, whether observed directly or indirectly.
  • total RNA may be used as a starting material.
  • the starting material may be mRNA, polyadenylated RNA, or RNA that has been purified or isolated in whole or in part.
  • the RNA may be in a sample, or aliquot thereof, from a cell or cell containing material, such as a biological sample from a human patient or animal subject.
  • RNA containing material is then used as a template for cDNA synthesis of a first, complementary, cDNA molecule (single stranded).
  • the cDNA will be representative of the reverse transcribed portion of the RNA population.
  • the RNA contains polyadenylated RNA, and the reverse transcription comprises use of an oligo dT primer and optionally random primers that are complementary to a multiplicity of RNA sequences and so molecules.
  • the random primers are biotinylated or otherwise labeled in an analogous manner that allows for subsequent purification and/or capture of the cDNA molecules. In other embodiments, it is the oligo dT, rather than random, primer that is biotinylated or otherwise labeled for purification and/or capture.
  • the cDNA molecule(s) are then used as a template, or starting material, for the annealing of DNA oligonucleotides comprising sequences complementary to sequence(s of interest (query sequence or sequences) as present on an RNA molecule that has been reverse transcribed into the cDNA.
  • DNA oligonucleotides comprising sequences complementary to sequence(s of interest (query sequence or sequences) as present on an RNA molecule that has been reverse transcribed into the cDNA.
  • a first oligonucleotide comprises a "Pl" primer (or forward primer) sequence at its 5' end to facilitate PCR amplification as discussed below.
  • This first oligonucleotide is extended to allow ligation to the second oligonucleotide, which comprises a "P2" primer (or reverse primer) sequence at its 3' end to facilitate PCR amplification as discussed below.
  • the "P2" containing oligonucleotide optionally includes, as shown in Figure 1, an "address" sequence which permits an alternative means of detection by real-time PCR as discussed below.
  • the "Pl" and "P2" containing oligonucleotide pairs may be used optionally in combination with one or more additional pairs comprising sequences complementary to one or more other sequences of interest present in other RNA molecules or other regions of the same RNA molecule.
  • the disclosure includes the use of additional pairs of oligonucleotides to permit multiplex detection of more than one RNA sequence to be detected.
  • the acts of annealing, extending, and ligating may be performed in a single tube or container for the reaction.
  • the resultant, ligated molecules are amplified by PCR with the "Pl" and "P2" primers (or common primers) to produce copies of an amplicon for subsequent real-time PCR analysis.
  • the PCR amplification will co-amplify all of the RNA sequences that are queried. This co-amplification reaction may advantageously be conducted in a single tube or container as well.
  • each RNA sequence in the amplified material may be performed in single-plex (where only one RNA sequence of interest is assayed) or in multi-plex (where more than one RNA sequence of interest is assayed) format using the common primers with an internal real-time PCR probe that is either within the targeted RNA sequence (not shown in Figure 1) or a probe that detects the "address" sequence as shown in Figure 1.
  • the probe may be complementary to the targeted RNA or "address" sequence or the same as the targeted RNA or "address” sequence as a design choice. The complementarity between the strands of the amplicons allows either strand to be detected in most cases.
  • a disclosed method may be used with oligonucleotides, for annealing, extension, ligation, and subsequent PCR amplification, that have already been designed or selected for use with other protocols.
  • Non-limiting examples include those where the amplicon(s) are detected by hybridization to a probe, optionally immobilized on a solid support.
  • a disclosed method may be advantageously used with samples containing degraded or compromised RNA as the input, or starting material.
  • samples containing degraded or compromised RNA include cell containing samples that have been formalin fixed and paraffin-embedded (FFPE samples).
  • starting materials include frozen or fresh cell or tissue samples.
  • a disclosed method may be considered to provide a means to analyzing global, or near global, gene expression from cells.
  • a method is used with a single cell or a homogenous cell population, such as one dissected away from, or otherwise isolated or purified from, contaminating cells beyond that possible by a simple biopsy.
  • a method is used to analyze expression of polyadenylated RNA from a human patient or animal subject.
  • a method of the disclosure may be used with the removal of contaminating cells (such as infiltrating lymphocytes or other immune system cells) that do not provide relevant or desirable information regarding the expression level(s) of interest.
  • the contaminating cells are not present to possibly affect the genes identified or the subsequent analysis of gene expression. Such contamination is present where a biopsy containing many cell types is used to generate gene expression profiles.
  • Preferred animals for the application of the present invention are mammals, particularly those important to agricultural applications (such as, but not limited to, cattle, sheep, horses, and other "farm animals"), animal models of prostate cancer, and animals for human companionship (such as, but not limited to, dogs and cats).
  • a disclosed method may be used to profile mRNAs that are highly degraded because the primers (P1/P2) and probe may be selected to target a relatively short mRNA sequence.
  • the sequence may be about 40, about 42, about 44, about 46, about 48, about 50 or about 52 or longer bases in length.
  • the sequence may be about 59, about 61, about 63, about 65, about 67, about 69 or longer in length.
  • the sequence may that present near a polyadenylated tail, or 3' end, of the RNA molecule. In some embodiments, this may be a sequence that is in whole, or in part, within the 3' untranslated region of the RNA molecule. In other embodiments, the sequence may include both translated and untranslated sequences.
  • a probe that detects an "address” sequence may be used as described herein.
  • the "address” sequence may be any suitably unique sequence selected by a skilled practitioner to facilitate its detection.
  • the presence of the "address” sequence adjacent to a targeted RNA sequence in the amplicon allows detection of the "address” sequence to serve as an indirect detection of the targeted sequence.
  • Real-time PCR allows quantitative measurements of a nucleic acid molecule, such as a DNA molecule, to be made with much more precision and reproducibility because it relies on threshold cycle (CT) values determined during the exponential phase of PCR rather than endpoint measurements.
  • CT threshold cycle
  • One type of real time PCR using a primer pair and a fluorogenic (dark-hole-quencher) probe (such as 5'-6-FAM/MGB), is based on the hydrolysis of the fluorogenic probe.
  • the probe contains a 5'-fluorophore and a 3'-quencher and anneals to a specific target sequence between the upstream and the downstream primers in a PCR system.
  • the 3'-terminus of the probe may be optionally blocked to prevent its use as a primer for strand extension.
  • the PCR reaction proceeds as the 5' to 3'-endonuclase activity of the thermal stable polymerase enzyme cleaves the fluorophore from the probe. Because the fluorophore is no longer in close proximity to the quencher its fluorescence becomes detectable. As the concentration of cleaved fluorophore in solution increases, the resultant fluorescent signal is monitored by real-time fluorometric analysis.
  • Fluorescence values are recorded during every cycle and represent the amount of product amplified to that point in the amplification reaction. The more templates present at the beginning of the reaction, the fewer number of cycles it takes to reach a point in which the fluorescence signal is first recorded as statistically significant above background, which is the definition of the (Ct) values.
  • the disclosure includes the use of a real-time PCR probe that is labeled with a donor fluorescent moiety and a second quencher or acceptor fluorescent moiety.
  • the detection methods of the real-time PCR assay further includes detecting the presence or generation of detectable fluorescence, and thus the absence or decrease in fluorescence resonance energy transfer (FRET) between the donor fluorescent moiety and the quencher or acceptor fluorescent moiety in the PRRSV probe.
  • FRET fluorescence resonance energy transfer
  • Detection of fluorescence is preferably the result of amplification using a (thermostable) polymerase enzyme having 5' to 3' exonuclease activity which cleaves the donor fluorescence moiety from the probe to result in a detectable signal.
  • the locations of the donor and quencher or acceptor moieties on the probe may be such that FRET may occur between the two moieties.
  • the disclosure contemplates the location of the donor moiety at or near the 5' end of the probe and the quencher or acceptor moiety at or near the 3' end of the probe with a separation of from about 14 to about 22 basepairs between the moieties, although other distances, such as from about 6, about 8, about 10, or about 12 basepairs may be used. Additional distances are about 14, about 16, about 18, about 20, or about 22 basepairs.
  • a probe can include a nucleic acid sequence that permits secondary structure formation (such as a hairpin) that results in spatial proximity between the donor and the quencher or acceptor fluorescent moiety.
  • a nucleic acid sequence that permits secondary structure formation (such as a hairpin) that results in spatial proximity between the donor and the quencher or acceptor fluorescent moiety.
  • Such a method does not require hydrolysis of the probe and has been referred to as the "molecular beacon” approach (see for example, Tyagi S et al. (1996) Molecular beacons: probes that fluoresce upon hybridization. Nat Biotechnol 14, 303-308).
  • a pair of probes is used, where one probe contains the donor moiety and the other probe contains the acceptor moiety.
  • Such an assay still includes performing at least one cycling step of the real-time PCR, wherein a cycling step comprises amplification and hybridization.
  • the hybridization includes contacting the target sequence with a pair of probes as described above.
  • the method further includes detecting the presence or absence of fluorescence resonance energy transfer (FRET) between the donor fluorescent moiety and the acceptor fluorescent moiety of the two probes.
  • FRET fluorescence resonance energy transfer
  • the presence or absence of FRET is indicative of the presence or absence of a nucleic acid sequence in a sample.
  • Such a method can further include determining the melting temperature between the amplification product and one or both of the probes. The melting temperature can confirm the presence or absence of a nucleic acid sequence.
  • a nucleic acid binding dye is used in place of any nucleic acid probe.
  • the dye-binding includes contacting the amplification product with a nucleic acid binding dye followed by detecting the presence or absence of binding of the nucleic acid binding dye to the amplification product.
  • the presence of binding is usually indicative of the presence of the amplified nucleic acid sequence, and the absence of binding is usually indicative of the absence thereof.
  • nucleic acid binding dyes include SybrGreen LRTM., SybrGold.RTM., and ethidium bromide.
  • a representative donor fluorescent moiety is FAM or 6-FAM
  • a representative quencher or acceptor fluorescent moiety is MGB.
  • Other non-limiting examples of a donor moiety include fluorescein, HEX, TET, TAM, ROX, Cy3, Alexa, and Texas Red while non- limiting examples of a quencher or acceptor fluorescent moiety include TAMRA, BHQ (black hole quencher), LCTM. -RED 640 (LightCycler.TM.-Red 640-N-hydroxysuccinimide ester), and cyanine dyes such as CY5.
  • any pair of donor and quencher/acceptor moieties may be used as long as they are compatible such that transmission may occur from the donor to the quencher/acceptor.
  • pairs of suitable donors and quenchers/acceptors are known in the art and are provided herein. The selection of a pair may be made by any means known in the art and may be confirmed by routine and repetitive testing for energy transfer or quenching of fluorescence.

Abstract

L'invention concerne l'utilisation d'une PCR en temps réel pour détecter le(s) niveau(x) d'expression de matériau génétique dans un échantillon. Le niveau d'expression de toute séquence génique, sous la forme de molécules d'ARN messager (ARNm), peut être détecté et/ou quantifié. Les procédés décrits peuvent être appliqués à un profilage d'ARN, ou pour déterminer les niveaux d'expression de multiples séquences géniques dans un échantillon biologique, comprenant un échantillon contenant de l'ARN relativement dégradé, tel qu'un échantillon FFPE.
PCT/US2008/065181 2007-05-29 2008-05-29 Pcr (amplification en chaîne par polymérase) en temps réel WO2008150937A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94068607P 2007-05-29 2007-05-29
US60/940,686 2007-05-29

Publications (2)

Publication Number Publication Date
WO2008150937A2 true WO2008150937A2 (fr) 2008-12-11
WO2008150937A3 WO2008150937A3 (fr) 2009-12-30

Family

ID=40094360

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/065181 WO2008150937A2 (fr) 2007-05-29 2008-05-29 Pcr (amplification en chaîne par polymérase) en temps réel

Country Status (1)

Country Link
WO (1) WO2008150937A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2256216A1 (fr) * 2009-04-30 2010-12-01 Steffen Mergemeier Système d'analyse utilisant une activité de nucléase d'une polymérase d'acide nucléique
US9376711B2 (en) 2011-07-13 2016-06-28 Qiagen Mansfield, Inc. Multimodal methods for simultaneous detection and quantification of multiple nucleic acids in a sample

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050053942A1 (en) * 2002-06-24 2005-03-10 Sakari Kauppinen Methods and systems for detection and isolation of a nucleotide sequence
US20070065846A1 (en) * 2002-03-13 2007-03-22 Baker Joffre B Gene expression profiling in biopsied tumor tissues

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070065846A1 (en) * 2002-03-13 2007-03-22 Baker Joffre B Gene expression profiling in biopsied tumor tissues
US20050053942A1 (en) * 2002-06-24 2005-03-10 Sakari Kauppinen Methods and systems for detection and isolation of a nucleotide sequence

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2256216A1 (fr) * 2009-04-30 2010-12-01 Steffen Mergemeier Système d'analyse utilisant une activité de nucléase d'une polymérase d'acide nucléique
EP2256215A1 (fr) * 2009-04-30 2010-12-01 Steffen Mergemeier Système d'analyse utilisant une activité de nucléase d'une polymérase d'acide nucléique
US9376711B2 (en) 2011-07-13 2016-06-28 Qiagen Mansfield, Inc. Multimodal methods for simultaneous detection and quantification of multiple nucleic acids in a sample

Also Published As

Publication number Publication date
WO2008150937A3 (fr) 2009-12-30

Similar Documents

Publication Publication Date Title
US11530450B2 (en) Methods, compositions, and kits for detecting allelic variants
US20200318186A1 (en) Nucleic Acid Probe and Method of Detecting Genomic Fragments
US9909179B2 (en) Single-cell nucleic acid analysis
EP1896617B1 (fr) Amplification multiplexe d'acides nucléiques courts
AU781136B2 (en) Methods and oligonucleotides for detecting nucleic acid sequence variations
US20020098484A1 (en) Method of analyzing single nucleotide polymorphisms using melting curve and restriction endonuclease digestion
CN101889096A (zh) 核酸扩增
CA2588865A1 (fr) Detection de variation d'acides nucleiques par un procede d'amplification par clivage
CN104164478A (zh) 一种基因单碱基变异的cras-pcr检测方法
EP1829964A1 (fr) Procede d'etude d'une sequence d'un gene
WO2013113748A1 (fr) Procédé pour détecter et génotyper un acide nucléique cible
TWI795626B (zh) 基於使用單核苷酸多型性標籤序列之單一檢測探針檢測多個目標的方法
RU2665631C2 (ru) Способ специфической идентификации последовательностей днк
WO2008150937A2 (fr) Pcr (amplification en chaîne par polymérase) en temps réel
US20180237853A1 (en) Methods, Compositions and Kits for Detection of Mutant Variants of Target Genes
CN112266950A (zh) 一种探针引物组合及其检测试剂盒
CN116179658B (zh) 一种荧光引物扩增阻滞突变系统及其应用
CN114250286B (zh) 用于核酸检测的组合、试剂盒及其应用
CN114686573B (zh) 一种检测靶核酸拷贝数重复的方法和试剂盒
AU2003294417A1 (en) Polynucleotide sequence detection assays and analysis
EP4350002A1 (fr) Detection of molecular analytes based on tailored probe competition
CN109312397A (zh) Penta E基因座多态性人体鉴定

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08769833

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08769833

Country of ref document: EP

Kind code of ref document: A2